Meeting Report
CAR T-Cell Therapy: On the Verge of Breakthrough in Many Hematologic Malignancies
Presented by Edward Stadtmauer, MD, and Patricia A. Mangan, RN, MSN, APRN-BC
University of Pennsylvania Abramson Cancer Center, Philadelphia
J Adv Pract Oncol 2017;8:228–231 |
https://doi.org/10.6004/jadpro.2017.8.3.3 |
© 2017 Harborside Press®
ABSTRACT
There have been promising results from clinical trials on the efficacy of engineering patients' immune cells to treat their cancers. CAR T-cell therapy also has unique toxicities advanced practitioners should be aware of.
For access to the full length article, please
sign in.
